Header Logo

MICHELLE A FANALE

TitleAssociate Professor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Crosswell HE, LaCasce AS, Bartlett NL, Straus DJ, Savage KJ, Zinzani PL, Collins GP, Fanale M, Fenton K, Dong C, Miao H, Grigg AP. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica. 2024 Mar 01; 109(3):982-987. PMID: 37794803; PMCID: PMC10905068.
      Citations:    Fields:    Translation:Humans
    2. Flora DR, Parsons SK, Liu N, Yu KS, Holmes K, Flores C, Fanale MA, Surinach A, Byrd R, Evens AM. Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey. Br J Haematol. 2024 Apr; 204(4):1262-1270. PMID: 38323849.
      Citations:    Fields:    
    3. Flora DR, Evens AM, Liu N, Yu KS, Byrd R, Fanale MA, Holmes K, Flores C, Surinach A, Parsons SK. The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional survey. Support Care Cancer. 2023 Nov 02; 31(12):664. PMID: 37914825; PMCID: PMC10620297.
      Citations:    Fields:    Translation:Humans
    4. Barta SK, Liu N, DerSarkissian M, Chang R, Ye M, Duh MS, Surinach A, Fanale M, Yu KS. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):e21-e32.e4. PMID: 37919137.
      Citations:    Fields:    Translation:Humans
    5. Evens AM, Yu KS, Liu N, Surinach A, Holmes K, Flores C, Fanale MA, Flora DR, Parsons SK. Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study. Future Oncol. 2024 Apr; 20(12):749-760. PMID: 37665273.
      Citations:    Fields:    Translation:Humans
    6. Yasenchak C, Liu N, Beeks A, Fanale M, Robert N, He D, Yu KS. Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncol Pract. 2023 Oct; 19(10):860-870. PMID: 37651672; PMCID: PMC10615434.
      Citations:    Fields:    Translation:Humans
    7. Burke JM, Liu N, Yu KS, Fanale MA, Surinach A, Flores C, Lisano J, Phillips T. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. Oncologist. 2023 06 02; 28(6):520-530. PMID: 36971492; PMCID: PMC10243782.
      Citations: 1     Fields:    Translation:Humans
    8. Phillips T, Migliaccio-Walle K, Yu KS, Bloudek B, Liu N, Fanale M, Burke JM. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leuk Lymphoma. 2023 05; 64(5):1017-1025. PMID: 37074674.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Winter A, Liu N, Surinach A, Fanale M, Yu KS, Narkhede M. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):527-534. PMID: 37121857.
      Citations: 1     Fields:    Translation:Humans
    10. Parsons SK, Yu KS, Liu N, Kumar S, Fanale MA, Holmes K, Flores C, Surinach A, Flora DR, Evens AM. Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study. JCO Oncol Pract. 2023 06; 19(6):e867-e876. PMID: 36947720; PMCID: PMC10332842.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    11. Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Alpdogan O, Suh C, Tobinai K, Shustov A, Yuen S, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S, Morschhauser F, Trneny M, Zinzani PL, Tr?mper L. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022 10 11; 6(19):5550-5555. PMID: 35470385; PMCID: PMC9647727.
      Citations:    Fields:    
    12. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755. PMID: 35952327; PMCID: PMC10489211.
      Citations:    
    13. Krishnan M, Bociek RG, Fanale M, Iyer SP, Lechowicz MJ, Bierman PJ, Armitage JO, Lunning M, Kallam A, Vose JM. Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. Ann Hematol. 2022 Feb; 101(2):335-340. PMID: 34668982.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    14. Straus DJ, Connors JM, Alekseev S, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J, Dlugosz-Danecka M, Ill?s ?, Zinzani PL. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021 Jun; 8(6):e410-e421. PMID: 34048680.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    15. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587. PMID: 33055173.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    16. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67. PMID: 32924687.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    17. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol. 2020 08 01; 38(22):2519-2529. PMID: 32453640; PMCID: PMC7392744.
      Citations: 16     Fields:    Translation:Humans
    18. Feldman T, Zou D, Rebeira M, Lee J, Fanale M, Manley T, Rao S, Feliciano J, Harris M, Kansal A. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL. Am J Manag Care. 2020 02 01; 26(2):e41-e49. PMID: 32059099.
      Citations: 1     Fields:    Translation:Humans
    19. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336. PMID: 31533521.
      Citations: 1     Fields:    Translation:Humans
    20. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 01; 105(1):e26-e28. PMID: 31073068; PMCID: PMC6939506.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    21. Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmaeli B. Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. Ophthalmic Plast Reconstr Surg. 2019 May/Jun; 35(3):243-246. PMID: 30124609.
      Citations: 2     Fields:    Translation:Humans
    22. von Tresckow B, Fanale M, Ardeshna KM, Chen R, Meissner J, Morschhauser F, Moskowitz C, Giezek H, Balakumaran A, Vo TT, Raut M, Brice P, Zinzani PL. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2019 11; 60(11):2705-2711. PMID: 31012356.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    23. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882. PMID: 30919940; PMCID: PMC6619290.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    24. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019 May; 41(5):1546. PMID: 30990235.
      Citations: 1     Fields:    
    25. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. 2019 05; 185(4):670-678. PMID: 30820940.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    26. Milgrom SA, Elhalawani H, Lee J, Wang Q, Mohamed ASR, Dabaja BS, Pinnix CC, Gunther JR, Court L, Rao A, Fuller CD, Akhtari M, Aristophanous M, Mawlawi O, Chuang HH, Sulman EP, Lee HJ, Hagemeister FB, Oki Y, Fanale M, Smith GL. A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Sci Rep. 2019 02 04; 9(1):1322. PMID: 30718585; PMCID: PMC6361903.
      Citations: 16     Fields:    Translation:HumansCells
    27. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Ann Hematol. 2019 May; 98(5):1169-1176. PMID: 30617643.
      Citations: 3     Fields:    Translation:Humans
    28. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Savage KJ, Yuen S, Iyer S, Hua Z, Little M, Rao S, Woolery J, Manley T, ECHELON-2 Study Group, Morschhauser F, Belada D, Ill?s ?, H?ttmann A, Zinzani PL, Tr?mper L. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 01 19; 393(10168):229-240. PMID: 30522922; PMCID: PMC6436818.
      Citations: 140     Fields:    Translation:HumansCTClinical Trials
    29. Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e609-e617. PMID: 30501868; PMCID: PMC6342507.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    30. Jensen GL, Dabaja BS, Pinnix CC, Gunther JR, Huen A, Duvic M, Oki Y, Fanale M, Hosing C, Milgrom SA. Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Rep Oncol. 2018 Sep-Dec; 11(3):721-728. PMID: 30519174; PMCID: PMC6276745.
      Citations:    
    31. Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki Y. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Hematol Oncol. 2019 Feb; 37(1):35-38. PMID: 30209819.
      Citations: 2     Fields:    Translation:Humans
    32. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61. PMID: 30360985; PMCID: PMC6371800.
      Citations: 2     Fields:    Translation:Humans
    33. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica. 2019 02; 104(2):e65-e67. PMID: 30190343; PMCID: PMC6355491.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    34. Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol. 2018 10 20; 36(30):3015-3022. PMID: 30179569.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    35. Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist. 2019 02; 24(2):219-228. PMID: 30108156; PMCID: PMC6369943.
      Citations: 12     Fields:    Translation:Humans
    36. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646. PMID: 30370365; PMCID: PMC6200878.
      Citations: 3     
    37. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019 04; 185(2):334-338. PMID: 29978452.
      Citations: 3     Fields:    Translation:Humans
    38. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018 Jun 22; 9(48):28897-28902. PMID: 29988979; PMCID: PMC6034756.
      Citations: 11     Fields:    
    39. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343. PMID: 29895624; PMCID: PMC5998935.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    40. Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:592-603. PMID: 30231316.
      Citations: 1     Fields:    Translation:Humans
    41. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569. PMID: 29723393.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    42. Pinnix CC, Huo J, Milgrom SA, Yehia ZA, Fanale M, Oki Y, Dabaja BS, Smith GL. Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. Adv Radiat Oncol. 2018 Jul-Sep; 3(3):372-381. PMID: 30202805; PMCID: PMC6128097.
      Citations: 1     
    43. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. 2018 09; 103(9):e416-e418. PMID: 29622656; PMCID: PMC6119133.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    44. Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659. PMID: 29616834; PMCID: PMC6363900.
      Citations: 1     Fields:    Translation:Humans
    45. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018 05 10; 36(14):1428-1439. PMID: 29584546; PMCID: PMC6075855.
      Citations: 187     Fields:    Translation:HumansCTClinical Trials
    46. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461. PMID: 29538376; PMCID: PMC5851529.
      Citations: 10     Fields:    Translation:Humans
    47. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):530-540. PMID: 29681481; PMCID: PMC7189963.
      Citations: 10     Fields:    Translation:Humans
    48. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018 05 10; 131(19):2120-2124. PMID: 29507077; PMCID: PMC5946765.
      Citations: 21     Fields:    Translation:Humans
    49. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609. PMID: 29501779; PMCID: PMC8212703.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    50. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2018 06; 40(6):1335. PMID: 29851218.
      Citations: 2     Fields:    
    51. Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018 04 01; 36(10):942-950. PMID: 29394125; PMCID: PMC5877802.
      Citations: 110     Fields:    Translation:HumansCellsCTClinical Trials
    52. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154. PMID: 29452771.
      Citations: 1     Fields:    Translation:Humans
    53. Watkins MP, Fanale MA, Bartlett NL. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):81-90. PMID: 29366607.
      Citations: 1     Fields:    Translation:HumansAnimals
    54. Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, Akhtari M, Allen PK, Atkinson BJ, Smith GL, Pinnix CC, Milgrom SA, Abou Yehia Z, Osborne EM, Oki Y, Lee H, Hagemeister F, Fanale MA. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018 02; 180(4):545-549. PMID: 29271057.
      Citations: 12     Fields:    Translation:HumansCells
    55. Milgrom SA, Pinnix CC, Gunther JR, Fanale M, Dabaja BS. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. Br J Haematol. 2019 01; 184(2):292-293. PMID: 29265334.
      Citations:    Fields:    Translation:Humans
    56. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676. PMID: 29237802; PMCID: PMC5935561.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    57. Fanale MA. Brentuximab vedotin for advanced Hodgkin's lymphoma. Lancet Oncol. 2017 12; 18(12):1566-1568. PMID: 29133015.
      Citations: 2     Fields:    Translation:Humans
    58. Akhtari M, Milgrom SA, Pinnix CC, Reddy JP, Dong W, Smith GL, Mawlawi O, Abou Yehia Z, Gunther J, Osborne EM, Andraos TY, Wogan CF, Rohren E, Garg N, Chuang H, Khoury JD, Oki Y, Fanale M, Dabaja BS. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018 01 04; 131(1):84-94. PMID: 29038339; PMCID: PMC5755043.
      Citations: 25     Fields:    Translation:Humans
    59. Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50. PMID: 29277360; PMCID: PMC8224469.
      Citations: 5     Fields:    Translation:HumansCells
    60. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 12 21; 130(25):2709-2717. PMID: 28974506; PMCID: PMC5746164.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    61. Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? Br J Haematol. 2017 11; 179(3):488-496. PMID: 28832956; PMCID: PMC5871231.
      Citations: 3     Fields:    Translation:Humans
    62. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870. PMID: 28792260.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    63. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Perales MA, Carpenter PA, Savani BN, Sureda A. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1826-1838. PMID: 28797780.
      Citations: 39     Fields:    Translation:HumansCells
    64. Connors JM, Ansell SM, Fanale M, Park SI, Younes A. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017 09 14; 130(11):1375-1377. PMID: 28733323; PMCID: PMC5766843.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    65. Pinnix CC, Andraos TY, Milgrom S, Fanale MA. The Management of Lymphoma in the Setting of Pregnancy. Curr Hematol Malig Rep. 2017 06; 12(3):251-256. PMID: 28470380; PMCID: PMC5650107.
      Citations: 7     Fields:    Translation:Humans
    66. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477. PMID: 28522441; PMCID: PMC5578726.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    67. KEYNOTE-087, Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 01; 35(19):2125-2132. PMID: 28441111; PMCID: PMC5791843.
      Citations: 323     Fields:    Translation:HumansCTClinical Trials
    68. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 05; 22(5):549-553. PMID: 28408615; PMCID: PMC5423503.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    69. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100. PMID: 28370694; PMCID: PMC6044206.
      Citations: 26     Fields:    Translation:Humans
    70. Pinnix CC, Fanale MA. Lymphoma and Pregnancy-Reply. JAMA Oncol. 2017 04 01; 3(4):567-568. PMID: 27978566.
      Citations: 1     Fields:    Translation:Humans
    71. Chihara D, Fanale MA. Management of Anaplastic Large Cell Lymphoma. Hematol Oncol Clin North Am. 2017 04; 31(2):209-222. PMID: 28340874.
      Citations: 6     Fields:    Translation:Humans
    72. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270. PMID: 28340281; PMCID: PMC5901692.
      Citations: 5     Fields:    Translation:Humans
    73. Casulo C, O'Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, Kahl BS, Little RF, Pinter-Brown L, Advani R, Horwitz S. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. J Natl Cancer Inst. 2017 02; 109(2). PMID: 28040682; PMCID: PMC6059211.
      Citations: 9     Fields:    Translation:HumansCells
    74. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758. PMID: 27983760; PMCID: PMC5836501.
      Citations: 27     Fields:    Translation:Humans
    75. Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer. 2017 Apr 15; 123(8):1363-1371. PMID: 27984652; PMCID: PMC5811230.
      Citations: 4     Fields:    Translation:Humans
    76. Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, Rohren E, Garg N, Chuang H, Yehia ZA, Reddy JP, Gunther JR, Khoury JD, Suki T, Osborne EM, Oki Y, Fanale M, Dabaja BS. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):333-338. PMID: 28068241; PMCID: PMC6033266.
      Citations: 3     Fields:    Translation:HumansCells
    77. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. PMID: 27589687; PMCID: PMC5341894.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    78. Abou Yehia Z, Mikhaeel GN, Smith G, Pinnix CC, Milgrom SA, Tang C, Jiang W, Fanale MA, Oki Y, Shank JH, Horace T, Reddy J, Akhtari M, Gunther JR, Suki T, Allen PK, Turner S, Mawlawi O, Dabaja BS. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma? Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):951-958. PMID: 27742539.
      Citations: 2     Fields:    Translation:Humans
    79. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. 2017 12; 179(5):851-854. PMID: 27502933; PMCID: PMC6063086.
      Citations: 6     Fields:    Translation:Humans
    80. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9. PMID: 27227654; PMCID: PMC7457973.
      Citations: 9     Fields:    Translation:Humans
    81. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299. PMID: 27448187.
      Citations: 12     Fields:    Translation:HumansCells
    82. Younes A, Santoro A, Shipp M, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A, Zinzani PL. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1283-94. PMID: 27451390; PMCID: PMC5541855.
      Citations: 342     Fields:    Translation:HumansCTClinical Trials
    83. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506. PMID: 27378601; PMCID: PMC5920532.
      Citations: 3     Fields:    Translation:Humans
    84. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151. PMID: 27351173.
      Citations: 25     Fields:    Translation:Humans
    85. Cheah CY, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA, Br?ckelmann PJ. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. Am J Hematol. 2016 09; 91(9):894-9. PMID: 27222367.
      Citations: 4     Fields:    Translation:Humans
    86. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. PMID: 27203405; PMCID: PMC4992444.
      Citations: 18     Fields:    Translation:Humans
    87. Savage KJ, Mottok A, Fanale M. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Hematol. 2016 Jul; 53(3):190-202. PMID: 27496311.
      Citations: 6     Fields:    Translation:HumansCells
    88. Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN, Yabe M. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88. PMID: 26872013.
      Citations: 14     Fields:    Translation:HumansCells
    89. Fanale M. New insights into NLPHL transformation. Blood. 2016 Apr 21; 127(16):1946-7. PMID: 27103741.
      Citations:    Fields:    Translation:Humans
    90. Gunther JR, Fanale MA, Reddy JP, Akhtari M, Smith GL, Pinnix CC, Milgrom SA, Yehia ZA, Allen PK, Osborne EM, Mawlawi O, Dabaja BS. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):110-8. PMID: 27325479; PMCID: PMC6047754.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    91. Press OW, Li H, Sch?der H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 06 10; 34(17):2020-7. PMID: 27069074; PMCID: PMC4966513.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    92. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, Fayad LE, Fisch MJ, Yeh ET. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study. J Card Fail. 2016 Jun; 22(6):433-8. PMID: 27079675.
      Citations: 31     Fields:    Translation:Humans
    93. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma. Biol Blood Marrow Transplant. 2016 07; 22(7):1333-1337. PMID: 27064056; PMCID: PMC5193224.
      Citations: 10     Fields:    Translation:Humans
    94. Chen R, Allibone S, Bartlett NL, Chen A, Pose K, Rich L, Bonthapally V, Garfin PM, Fanale M, Brice P. Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. Onco Targets Ther. 2016; 9:2027-34. PMID: 27103829; PMCID: PMC4827881.
      Citations: 1     
    95. Sathyanarayanan V, Foo WC, Fanale M, Westin J. Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma: A Perplexing Entity. Clin Lymphoma Myeloma Leuk. 2016 05; 16(5):e65-70. PMID: 27050323.
      Citations: 1     Fields:    Translation:Humans
    96. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8. PMID: 26795083.
      Citations: 5     Fields:    Translation:Humans
    97. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. 2016 11; 175(3):531-533. PMID: 26683805.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    98. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10; 34(2):160-8. PMID: 26628470; PMCID: PMC4872006.
      Citations: 86     Fields:    Translation:Humans
    99. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol. 2015 Sep 25; 10:206. PMID: 26407853; PMCID: PMC4582821.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    100. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140; PMCID: PMC4715651.
      Citations: 28     Fields:    Translation:HumansCells
    101. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16. PMID: 26260306.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    102. Reddy JP, Akhtari M, Smith GL, Pinnix C, Osborne EM, Gunther JR, Allen PK, Yehia ZA, Fanale M, Rodriguez MA, Fowler N, Milgrom SA, Wogan CF, Dabaja BS. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):664-670.e2. PMID: 26321471.
      Citations: 1     Fields:    Translation:Humans
    103. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015 Nov; 171(4):463-70. PMID: 26213141; PMCID: PMC5278973.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    104. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. PMID: 26071868; PMCID: PMC4781754.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    105. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82. PMID: 25863764; PMCID: PMC4418193.
      Citations: 43     Fields:    Translation:Humans
    106. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21. PMID: 25863759; PMCID: PMC4418191.
      Citations: 13     Fields:    Translation:Humans
    107. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23. PMID: 25828695; PMCID: PMC5278955.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    108. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015 Jun; 169(5):689-93. PMID: 25818067; PMCID: PMC5279064.
      Citations: 17     Fields:    Translation:HumansCells
    109. Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. Lancet Haematol. 2015 Apr; 2(4):e166-74. PMID: 26687959.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    110. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leuk Lymphoma. 2016 Feb; 57(2):445-447. PMID: 25804933; PMCID: PMC5215977.
      Citations: 3     Fields:    
    111. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015 May; 21(5):855-9. PMID: 25652691; PMCID: PMC4408269.
      Citations: 11     Fields:    Translation:Humans
    112. Cheah CY, Oki Y, Fanale MA. Novel treatments for T-cell lymphoma. Am Soc Clin Oncol Educ Book. 2015; e468-78. PMID: 25993211.
      Citations: 1     Fields:    Translation:Humans
    113. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8. PMID: 25439689; PMCID: PMC4370362.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    114. Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leuk Lymphoma. 2015 Apr; 56(4):1151-3. PMID: 25110824.
      Citations: 3     Fields:    Translation:Humans
    115. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468; PMCID: PMC4344896.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    116. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 Oct 01; 32(28):3137-43. PMID: 25135998; PMCID: PMC4171358.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    117. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat. 2014 Aug; 147(1):1-14. PMID: 25073777.
      Citations: 33     Fields:    Translation:Humans
    118. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct; 167(2):207-13. PMID: 25040450.
      Citations: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    119. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84. PMID: 25039868; PMCID: PMC5279071.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    120. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      Citations: 105     Fields:    Translation:Humans
    121. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 Mar 19; 7:24. PMID: 24642247; PMCID: PMC3994656.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    122. Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014 Oct; 55(10):2328-34. PMID: 24359243.
      Citations: 18     Fields:    Translation:Humans
    123. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6. PMID: 24386943; PMCID: PMC5308126.
      Citations: 15     Fields:    Translation:Humans
    124. Fanale M. A novel prognostic scoring system for NLPHL. Blood. 2013 Dec 19; 122(26):4154-5. PMID: 24357707.
      Citations: 2     Fields:    Translation:HumansCells
    125. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77. PMID: 24332512; PMCID: PMC3922714.
      Citations: 225     Fields:    Translation:HumansCTClinical Trials
    126. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec; 14(13):1348-56. PMID: 24239220.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    127. Fanale M, Assouline S, Kuruvilla J, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS, Solal-C?ligny P. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol. 2014 Jan; 164(2):258-65. PMID: 24219359; PMCID: PMC5308127.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    128. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90. PMID: 24097867; PMCID: PMC4409814.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    129. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20. PMID: 24117234; PMCID: PMC5278952.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    130. Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, Younes A, Morschhauser F, McMillan A, Horning SJ. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013 Nov; 54(11):2531-3. PMID: 23617324.
      Citations: 41     Fields:    Translation:Humans
    131. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013 Jun; 19(6):991-4. PMID: 23507470; PMCID: PMC4411554.
      Citations: 5     Fields:    Translation:Humans
    132. Fanale M. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? Hematology Am Soc Hematol Educ Program. 2013; 2013:406-13. PMID: 24319212.
      Citations: 4     Fields:    Translation:HumansCells
    133. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):99-105. PMID: 23276888; PMCID: PMC3881262.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    134. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012 Nov 20; 30(33):4161-7. PMID: 22965964; PMCID: PMC5950499.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    135. Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist. 2012; 17(8):1073-80. PMID: 22855426; PMCID: PMC3425525.
      Citations: 10     Fields:    Translation:Humans
    136. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012 Aug 01; 30(22):2776-82. PMID: 22753910; PMCID: PMC5950497.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    137. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23. PMID: 22677155.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    138. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1613-23. PMID: 22645177; PMCID: PMC3429305.
      Citations: 17     Fields:    Translation:HumansCells
    139. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012 Jun 20; 30(18):2190-6. PMID: 22614995.
      Citations: 330     Fields:    Translation:HumansCTClinical Trials
    140. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma. 2012 May; 53(5):990-2. PMID: 21988665.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    141. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012 Mar 01; 119(9):2171-2. PMID: 22383790.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    142. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8. PMID: 22371887; PMCID: PMC3359733.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    143. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012 Jan 01; 18(1):248-55. PMID: 22080439.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    144. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec; 12(13):1222-8. PMID: 22033282; PMCID: PMC5042214.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    145. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar; 53(3):499-502. PMID: 21859247; PMCID: PMC4245073.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    146. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol. 2011 Jul; 154(2):284-6. PMID: 21517809.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    147. Fanale MA, Younes A. Nodular lymphocyte predominant Hodgkin's lymphoma. Cancer Treat Res. 2008; 142:367-81. PMID: 18283795.
      Citations: 3     Fields:    Translation:Humans
    148. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs. 2007; 67(3):333-50. PMID: 17335294.
      Citations: 32     Fields:    Translation:Humans
    149. Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer. 2005 Oct; 6(4):354-6. PMID: 16277887.
      Citations: 16     Fields:    Translation:Humans
    150. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. Surgery. 2004 Aug; 136(2):437-42. PMID: 15300212.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    151. Petersen WO, Trapp MA, Fanale MA, Kaur JS. Evaluating the WEB training program for cancer screening in Native American women. Holist Nurs Pract. 2003 Sep-Oct; 17(5):262-75. PMID: 14596376.
      Citations:    Fields:    Translation:HumansPHPublic Health
    152. Comparison of survival in patients with t cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biology of Blood and Marrow Transplantation. 21:855-859.
    153. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. British Journal of Haematology.
    154. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. British Journal of Haematology.
    155. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma. Leukemia and Lymphoma.
    156. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging. Journal of Clinical Oncology. 34:2020-2027.
    157. A novel prognostic scoring system for NLPHL. Blood. 122:4154-4155.
    158. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin. The Lancet Oncology. 17:1283-1294.
    159. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    160. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology.
    161. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiation Oncology. 10.
    162. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation.
    163. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. Journal of Clinical Oncology. 34:160-168.
    164. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 7:67521-67531.
    165. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    166. Nodular lymphocyte-predominant hodgkin lymphoma. Hematologic Malignancies. 6:287-295.
    167. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    168. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. International Journal of Radiation Oncology Biology Physics. 96:951-958.
    169. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics. 96:110-118.
    170. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology.
    171. Nodular lymphocyte predominant Hodgkin's lymphoma. 367-381.
    172. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.
    173. Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. OncoTargets and Therapy. 9:2027-2034.
    174. Nodular lymphocyte-predominant hodgkin lymphoma. 287-295.
    175. Nodular lymphocyte-predominant Hodgkin lymphoma. Seminars in Hematology. 53:190-202.
    176. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. The Lancet Oncology. 15:69-77.
    177. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 16:122-128.
    178. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    179. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology.
    180. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy. Journal of Cardiac Failure. 22:433-438.
    181. Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma. Clinical Lymphoma, Myeloma and Leukemia.
    182. Hodgkin lymphoma. 225-239.
    183. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma. Annals of Oncology. 26:2490-2495.
    184. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics. 97:333-338.
    185. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.
    FANALE's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (413)
    Explore
    _
    Co-Authors (123)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _